Chiome Bioscience (TSE:4583) EV-to-EBIT : -4.18 (As of May. 27, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Chiome Bioscience's Enterprise Value is 円5,394.3 Mil. Chiome Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was 円-1,289.0 Mil. Therefore, Chiome Bioscience's EV-to-EBIT for today is -4.18.

The historical rank and industry rank for Chiome Bioscience's EV-to-EBIT or its related term are showing as below:

TSE:4583' s EV-to-EBIT Range Over the Past 10 Years
Min: -123.89 Med: -5.35 Max: -1.3
Current: -4.18

During the past 13 years, the highest EV-to-EBIT of Chiome Bioscience was -1.30. The lowest was -123.89. And the median was -5.35.

TSE:4583's EV-to-EBIT is ranked worse than
100% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs TSE:4583: -4.18

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Chiome Bioscience's Enterprise Value for the quarter that ended in Mar. 2024 was 円6,955.5 Mil. Chiome Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was 円-1,289.0 Mil. Chiome Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -18.53%.

Chiome Bioscience EV-to-EBIT Historical Data

The historical data trend for Chiome Bioscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience EV-to-EBIT Chart

Chiome Bioscience Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-3.29

-3.75

-4.33

-5.72

-5.01

Chiome Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-7.77	-7.37	-5.82	-5.01	-5.40

Competitive Comparison of Chiome Bioscience's EV-to-EBIT

For the Biotechnology subindustry, Chiome Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chiome Bioscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's EV-to-EBIT falls into.

Chiome Bioscience EV-to-EBIT Calculation

Chiome Bioscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	5394.292	/	-1289.049
	=	-4.18

Chiome Bioscience's current Enterprise Value is 円5,394.3 Mil.
Chiome Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,289.0 Mil.

Chiome Bioscience (TSE:4583) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Chiome Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-1289.049	/	6955.5145
	=	-18.53 %

Chiome Bioscience's Enterprise Value for the quarter that ended in Mar. 2024 was 円6,955.5 Mil.
Chiome Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,289.0 Mil.

Chiome Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience (TSE:4583) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines